Immunohistochemical (IHC) markers in the differential diagnosis of endometrial carcinomas
| vim | ER | PR | ARID1A | β-cat | AMACR | HNF1β | Napsin A | p53 | p16 | Specific | |
| Endometrial tumours | |||||||||||
| EMC | + | + | + | M>wt | M>wt | +/− | − | − | wt>M | −/+ | PTEN and MMR loss |
| USC | + | − | − | wt | wt | − | −/+ | − | M | + | CCNE1 amplification |
| CCC | + | − | − | wt | wt | −/+ | + | +/− | wt>M | − | MMR loss |
| UC | − | − | − | wt | M>wt | NA | − | NA | M>wt | −/+ | E-cadherin and MMR loss |
| MMMT | + | −/+ | −/+ | wt>M | wt | NA | − | NA | M | + | WT1, desmin, CD10, h- caldesmon, myogenin, S100, Myo-D1. Biphasic pattern |
ARID1A M consists in the loss of IHC staining, while ARID1A wt is nuclear staining; p53 M corresponds to intense and diffuse positivity in ≥60% of cells or complete negativity; p53 wt is the presence of rare cells weakly positive or positivity in <60% of cells. β-cat M is nuclear positivity; β-cat wt is cytoplasm, membrane positivity or negativity.
β-cat, β-catenin; CCC, clear cell carcinoma; EMC, endometrioid carcinoma; M, mutant pattern; MMMT, malignant mixed Müllerian tumour; MMR, DNA mismatch repair genes; NA, not available; UC, undifferentiated carcinoma; USC, uterine serous carcinoma; wt, wild-type pattern.